PVLA Earnings
Thursday, May 14 2026
EPS Estimate
$-0.93
$-1.15 – $-0.77
Current Price
$123.59
Our Position
bullish · highPVLA short interest falls 9% to 1.98M
structured data
est. revisions falling
(-5.3pp / 30d)
Reduced short interest suggests growing investor confidence in Palvella's regulatory and commercial prospects, supporting its near-term FDA approval path.
Watch: Monitor the FDA New Drug Application submission timing in H2 2026 for impact on approval and share momentum.
Data Signal Summary
2 bullish
2 bearish
Estimates down -5%
Insider buying cluster
Put/call 0.1 (bullish skew)
Price downtrend
Key Context
Insider Activity
mixed
Price Trend
downtrend
From 52w High
-5.4%
Est. Revisions (30d)
-5.0% 3up/4dn
Analyst Target (mean)
$230 $205–$270 +86%
Options P/C Ratio
0.05
Est. Dispersion
41% 11 analysts
Insider Cluster
strong buy
Recent Activity
insider trades
13 transactions
Buy
·
JENKINS GEORGE M (Director)
·445 shares
·$49,974
Sell
·
GOIN KATHLEEN (Chief Operating Officer)
·4,302 shares
·$507,611
Exercise
·
GOIN KATHLEEN (Chief Operating Officer)
·4,302 shares
·$34,883
Buy
·
JENKINS GEORGE M (Director)
·4,000 shares
·$500,000
Buy
·
HERON ELAINE J (Director)
·2,400 shares
·$300,000
8 more
Sell
·
GOIN KATHLEEN
·4,302 shr
·$341,564
Sell
·
GOIN KATHLEEN
·4,302 shr
·$419,983
Sell
·
GOIN KATHLEEN
·4,302 shr
·$415,023
Sell
·
GOIN KATHLEEN
·4,302 shr
·$370,965
Buy
·
JENKINS GEORGE M
·4,990 shr
·$100,797
Buy
·
JENKINS GEORGE M
·4,000 shr
·$51,720
Buy
·
ADAR1 CAPITAL MANAGEMENT LLC
·6,000 shr
·$92,326
Sell
·
GOIN KATHLEEN
·4,302 shr
·$547,399
Explore more
